Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
Biofrontera (NASDAQ:BFRI), a biopharmaceutical company focused on dermatological products commercialization, has scheduled its Second Quarter 2025 Financial Results announcement for August 13, 2025 after market close.
The company will host a conference call and webcast to discuss the results on Thursday, August 14, 2025, at 10:00 AM ET. Investors can access the call via U.S. toll-free number (1-877-877-1275) or international number (1-412-858-5202).
Biofrontera (NASDAQ:BFRI), un'azienda biofarmaceutica specializzata nella commercializzazione di prodotti dermatologici, ha programmato l'annuncio dei Risultati Finanziari del Secondo Trimestre 2025 per il 13 agosto 2025 dopo la chiusura del mercato.
L'azienda terrà una conference call e una webcast per discutere i risultati il giovedì 14 agosto 2025, alle 10:00 ET. Gli investitori potranno partecipare alla chiamata tramite il numero verde statunitense (1-877-877-1275) o il numero internazionale (1-412-858-5202).
Biofrontera (NASDAQ:BFRI), una compañía biofarmacéutica enfocada en la comercialización de productos dermatológicos, ha programado el anuncio de sus Resultados Financieros del Segundo Trimestre de 2025 para el 13 de agosto de 2025 después del cierre del mercado.
La compañía realizará una llamada de conferencia y una transmisión en línea para discutir los resultados el jueves 14 de agosto de 2025, a las 10:00 AM ET. Los inversores pueden acceder a la llamada mediante el número gratuito en EE.UU. (1-877-877-1275) o el número internacional (1-412-858-5202).
Biofrontera (NASDAQ:BFRI)는 피부과 제품 상용화에 중점을 둔 바이오제약 회사로, 2025년 2분기 재무 결과를 2025년 8월 13일 장 마감 후에 발표할 예정입니다.
회사는 2025년 8월 14일 목요일 오전 10시(동부 시간)에 결과를 논의하기 위해 컨퍼런스 콜과 웹캐스트를 진행합니다. 투자자들은 미국 무료 전화번호(1-877-877-1275) 또는 국제 전화번호(1-412-858-5202)를 통해 참여할 수 있습니다.
Biofrontera (NASDAQ:BFRI), une société biopharmaceutique spécialisée dans la commercialisation de produits dermatologiques, a prévu l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 13 août 2025 après la clôture du marché.
La société organisera une conférence téléphonique et une webdiffusion pour discuter des résultats le jeudi 14 août 2025 à 10h00 ET. Les investisseurs peuvent accéder à l'appel via le numéro vert américain (1-877-877-1275) ou le numéro international (1-412-858-5202).
Biofrontera (NASDAQ:BFRI), ein biopharmazeutisches Unternehmen, das sich auf die Vermarktung dermatologischer Produkte spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 13. August 2025 nach Börsenschluss geplant.
Das Unternehmen wird am Donnerstag, den 14. August 2025, um 10:00 Uhr ET eine Telefonkonferenz und Webcast veranstalten, um die Ergebnisse zu besprechen. Investoren können die Telefonkonferenz über die gebührenfreie US-Nummer (1-877-877-1275) oder die internationale Nummer (1-412-858-5202) erreichen.
- None.
- None.
Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am Eastern Time.
Conference Call and Webcast Information
| Event: | Biofrontera Inc. Second Quarter 2025 Financial Results and Business Update Conference Call |
| Date: | Thursday, August 14, 2025 |
| Time: | 10:00am ET |
| Conference Call: | 1-877-877-1275 (U.S.) 1-412-858-5202 (international) |
| Webcast: | Webcast | Second Quarter 2025 Financial Results and Business Update Conference Call |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com
FAQ
When will Biofrontera (BFRI) release Q2 2025 earnings?
How can investors join Biofrontera's Q2 2025 earnings call?
What is Biofrontera's (BFRI) main business focus?
What period will Biofrontera's Q2 2025 earnings report cover?
